{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:01:33Z","timestamp":1760101293834,"version":"3.37.3"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We compared the reduction in pain and opioid consumption in patients with chronic spinal pain on concomitant gabapentinoids and opioids with patients using opioids only.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>This was a retrospective chart review of patients with chronic neck or low back pain who were on opioids with at least a 24-month follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Single-center pain clinic in an urban setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Subjects<\/jats:title>\n                  <jats:p>167 patients with chronic spinal pain lasting at least six\u2009months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients on gabapentin or pregabalin were included in the gabapentinoid group, while the other patients were included in the non-gabapentinoid group. Primary outcome was assessment of pain scores measured via a numeric rating scale (NRS), and secondary outcomes were response to the treatment (&amp;gt;2 point reduction on NRS) and daily opioid use measured in morphine milliequivalents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Pain scores were reduced in the first six\u2009months and plateaued after that in both groups. At the end of 24\u2009months, the average pain score was 6.71 in the gabapentinoid group, while the average pain score was 7.18 in the non-gabapentinoid group. There was no statistical significance between the groups (p\u2009=\u20090.28). There was no difference in response to treatment in gabapentinoid group (33.3%) when compared with non-gabapentinoid group (32.7%). We also failed to find any significant difference in daily opioid usage between the two groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Gabapentinoids may not lead to reduction in pain or opioid consumption in patients with chronic spinal pain. A careful approach must be adopted while prescribing gabapentinoids in the chronic spinal pain patient population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/pm\/pnab006","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T18:45:07Z","timestamp":1610563507000},"page":"1760-1766","source":"Crossref","is-referenced-by-count":6,"title":["A Retrospective Analysis of Gabapentinoid and Opioids to Opioid Monotherapy for Pain Relief in Patients with Chronic Neck and Low Back Pain"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-1495","authenticated-orcid":false,"given":"Nebojsa Nick","family":"Knezevic","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, Illinois"},{"name":"Department of Anesthesiology, University of Illinois, Chicago, Illinois"},{"name":"Department of Surgery, University of Illinois, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tabish","family":"Aijaz","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Camacho-Ortega","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth D","family":"Candido","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, Illinois"},{"name":"Department of Anesthesiology, University of Illinois, Chicago, Illinois"},{"name":"Department of Surgery, University of Illinois, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"issue":"5","key":"2021080708522535700_pnab006-B1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","article-title":"A clinical overview of off-label use of gabapentinoid drugs","volume":"179","author":"Goodman","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"2","key":"2021080708522535700_pnab006-B2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","article-title":"Gabapentinoid use in the United States 2002 through 2015","volume":"178","author":"Johansen","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"5","key":"2021080708522535700_pnab006-B3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/ane.13075","article-title":"Therapeutic drug monitoring of gabapentin in various indications","volume":"139","author":"Larsen Burns","year":"2019","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"2021080708522535700_pnab006-B4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3928\/02793695-20131217-01","article-title":"Gabapentin for substance use disorders: Is it safe and appropriate?","volume":"52","author":"Howland","year":"2014","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"issue":"10","key":"2021080708522535700_pnab006-B5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jpain.2018.04.004","article-title":"Prescription medication use among community-based U.S. adults with chronic low back pain: A cross-sectional population based study","volume":"19","author":"Shmagel","year":"2018","journal-title":"J Pain"},{"issue":"1","key":"2021080708522535700_pnab006-B6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4103\/sni.sni_420_17","article-title":"Gabapentin-related suicide: Myth or fact?","volume":"9","author":"Ghaly","year":"2018","journal-title":"Surg Neurol Int"},{"issue":"9","key":"2021080708522535700_pnab006-B7","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/aas.12766","article-title":"Gabapentin for post-operative pain management: A systematic review with meta-analyses and trial sequential analyses","volume":"60","author":"Fabritius","year":"2016","journal-title":"Acta Anaesthesiol Scand"},{"issue":"10","key":"2021080708522535700_pnab006-B8","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1093\/pm\/pnaa017","article-title":"Effects of acetaminophen, NSAIDs, gabapentinoids, and their combinations on postoperative pulmonary complications after total hip or knee arthroplasty","volume":"21","author":"Ohnuma","year":"2020","journal-title":"Pain Med"},{"issue":"20","key":"2021080708522535700_pnab006-B9","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.2018.12358","article-title":"Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993\u20132017","volume":"320","author":"Montastruc","year":"2018","journal-title":"JAMA"},{"issue":"13","key":"2021080708522535700_pnab006-B10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2165\/00023210-200317130-00004","article-title":"Gabapentin: In postherpetic neuralgia","volume":"17","author":"Curran","year":"2003","journal-title":"CNS Drugs"},{"issue":"1","key":"2021080708522535700_pnab006-B11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.23907\/2017.012","article-title":"Gabapentin in mixed drug fatalities: Does this frequent analyte deserve more attention?","volume":"7","author":"Finlayson","year":"2017","journal-title":"Acad Forensic Pathol"},{"issue":"2","key":"2021080708522535700_pnab006-B12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/phar.2218","article-title":"Potentially unsafe chronic medication use among older adult chronic opioid users","volume":"39","author":"Silva Almodovar","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2021080708522535700_pnab006-B13"},{"issue":"2","key":"2021080708522535700_pnab006-B14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"issue":"5","key":"2021080708522535700_pnab006-B15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40263-019-00623-5","article-title":"Revisiting tramadol: A multi-modal agent for pain management","volume":"33","author":"Barakat","year":"2019","journal-title":"CNS Drugs"},{"issue":"7","key":"2021080708522535700_pnab006-B16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.7326\/M16-2458","article-title":"Systemic pharmacologic therapies for low back pain: A systematic review for an American college of physicians clinical practice guideline","volume":"166","author":"Chou","year":"2017","journal-title":"Ann Intern Med"},{"issue":"7","key":"2021080708522535700_pnab006-B17","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/j.pain.0000000000000554","article-title":"A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component","volume":"157","author":"Atkinson","year":"2016","journal-title":"Pain"},{"key":"2021080708522535700_pnab006-B18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jsat.2018.06.008","article-title":"US hospital discharges documenting patient opioid use disorder without opioid overdose or treatment services, 2011\u20132015","volume":"92","author":"Peterson","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"2021080708522535700_pnab006-B19","doi-asserted-by":"crossref","first-page":"233339281772742","DOI":"10.1177\/2333392817727424","article-title":"Who is overdosing? An updated picture of overdose deaths from 2008 to 2015","volume":"4","author":"Eigner","year":"2017","journal-title":"Health Serv Res Manag Epidemiol"},{"issue":"7","key":"2021080708522535700_pnab006-B20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7326\/0003-4819-147-7-200710020-00008","article-title":"Medications for acute and chronic low back pain: A review of the evidence for an American Pain Society\/American College of Physicians clinical practice guideline","volume":"147","author":"Chou","year":"2007","journal-title":"Ann Intern Med"},{"issue":"4","key":"2021080708522535700_pnab006-B21","first-page":"E429","article-title":"Comparison of the efficacy of a gabapentinoid with an opioid versus an opioid alone in patients with spinal cord stimulation","volume":"21","author":"Jang","year":"2018","journal-title":"Pain Physician"},{"issue":"4","key":"2021080708522535700_pnab006-B22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/jbcr\/irz036","article-title":"The effects of early neuropathic pain control with gabapentin on long-term chronic pain and itch in burn patients","volume":"40","author":"Kneib","year":"2019","journal-title":"J Burn Care Res"},{"issue":"6","key":"2021080708522535700_pnab006-B23","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/add.14412","article-title":"Rising pregabalin use and misuse in Australia: Trends in utilization and intentional poisonings","volume":"114","author":"Cairns","year":"2019","journal-title":"Addiction"},{"issue":"4","key":"2021080708522535700_pnab006-B24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40261-017-0616-y","article-title":"Intentional drug overdose involving pregabalin and gabapentin: Findings from the National Self-Harm Registry Ireland, 2007\u20132015","volume":"38","author":"Daly","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"1","key":"2021080708522535700_pnab006-B25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/bcp.12277","article-title":"Misuse of the \u03b3-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK","volume":"78","author":"Kapil","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2021080708522535700_pnab006-B26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/YIC.0000000000000147","article-title":"Pregabalin for generalized anxiety disorder: An updated systematic review and meta-analysis","volume":"32","author":"Generoso","year":"2017","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"2021080708522535700_pnab006-B27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40263-017-0467-3","article-title":"Pregabalin use among users of illicit drugs: A cross-sectional survey in Southern Germany","volume":"31","author":"Snellgrove","year":"2017","journal-title":"CNS Drugs"},{"key":"2021080708522535700_pnab006-B28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.forsciint.2018.01.025","article-title":"Illicit and prescription drug misuse as reported to the Maine Diversion Alert Program","volume":"285","author":"Piper","year":"2018","journal-title":"Forensic Sci Int"},{"issue":"2","key":"2021080708522535700_pnab006-B29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.24869\/psyd.2018.142","article-title":"On the addictive power of gabapentinoids: A mini-review","volume":"30","author":"Bonnet","year":"2018","journal-title":"Psychiatr Danub"},{"issue":"9","key":"2021080708522535700_pnab006-B30","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/pds.4230","article-title":"Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: Diversion rates and qualitative research findings","volume":"26","author":"Buttram","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"2021080708522535700_pnab006-B31","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s11126-016-9421-7","article-title":"Abuse of gabapentin is associated with opioid addiction","volume":"87","author":"Bastiaens","year":"2016","journal-title":"Psychiatr Q"},{"issue":"7","key":"2021080708522535700_pnab006-B32","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","article-title":"A decade of gabapentinoid misuse: An analysis of the European Medicines Agency's \u2018Suspected Adverse Drug Reactions\u2019 Database","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs"},{"issue":"5","key":"2021080708522535700_pnab006-B33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.amepre.2018.12.009","article-title":"U.S. Emergency department visits resulting from nonmedical use of pharmaceuticals, 2016","volume":"56","author":"Geller","year":"2019","journal-title":"Am J Prev Med"},{"issue":"3","key":"2021080708522535700_pnab006-B34","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/adb.12538","article-title":"Addiction-related interactions of pregabalin with morphine in mice and humans: Reinforcing and inhibiting effects","volume":"23","author":"Vashchinkina","year":"2018","journal-title":"Addict Biol"},{"issue":"7","key":"2021080708522535700_pnab006-B35","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse, and diversion: A systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"issue":"5","key":"2021080708522535700_pnab006-B36","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/pds.4771","article-title":"The diversion of nonscheduled psychoactive prescription medications in the United States, 2002 to 2017","volume":"28","author":"Kurtz","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"2021080708522535700_pnab006-B37","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/1556-4029.14021","article-title":"Tharp AM, Hobron K, Wright T. Gabapentin-related Deaths: Patterns of Abuse and Postmortem Levels","volume":"64","year":"2019","journal-title":"J Forensic Sci"},{"issue":"10","key":"2021080708522535700_pnab006-B38","doi-asserted-by":"crossref","first-page":"e1002396","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"key":"2021080708522535700_pnab006-B39","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.2147\/JPR.S144963","article-title":"Risk of respiratory depression with opioids and concomitant gabapentinoids","volume":"10","author":"Savelloni","year":"2017","journal-title":"J Pain Res"},{"issue":"4","key":"2021080708522535700_pnab006-B40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4997\/JRCPE.2017.402","article-title":"Gabapentin and pregabalin: Do the benefits outweigh the harms?","volume":"47","author":"Morrison","year":"2017","journal-title":"J R Coll Physicians Edinb"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/painmedicine\/advance-article-pdf\/doi\/10.1093\/pm\/pnab006\/36747206\/pnab006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/22\/8\/1760\/39607046\/pnab006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/22\/8\/1760\/39607046\/pnab006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T18:20:07Z","timestamp":1628360407000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/22\/8\/1760\/6121307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,1,27]]},"published-print":{"date-parts":[[2021,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnab006","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"type":"print","value":"1526-2375"},{"type":"electronic","value":"1526-4637"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,1,27]]}}}